StockTipsArenaBeta

BUY Lupin Limited — Somil Mehta, Sharekhan

BUYLupin Limited

bySomil Mehta, SharekhanHorizon: NA (inferred Swing (≤2wk))12 Apr 2026via CNBC Awaaz.

Entry₹2,333.8Inferred
Target₹2,400
Total upside +2.84% (call closed)
Stop loss₹2,090-10.45% risk
At expiry₹2,32527 Apr 2026, 3:30 pm
Expired-0.38%
Follow Somil Mehta for new calls(24% target hit, 184 closed calls)Get alertsWatch LUPIN for new buy/sell callsGet alertsSee 126 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 8 Sept, 11:17 am IST
2 supporting0 opposing
Supports the BUY call (2)

Lupin Limited has launched Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States.

BSE · Company Update·22 Apr · 5d ago

(opens in new tab)

1 advisor has an active short-term BUY call on this stock

Advisor consensus · adjacent horizon·6 Apr · 3w ago

Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.